Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy

Next Previous
X
Search
Trial Profile

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aficamten (Primary) ; Disopyramide
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions
  • Acronyms REDWOOD-HCM; REDWOOD-HCM
  • Sponsors Cytokinetics

    • Most Recent Events

    • 01 Nov 2024 Results assessing safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy , published in the Journal of Cardiac Failure.
    • 12 Jan 2024 Last checked against the ClinicalTrials.gov record.
    • 03 Aug 2023 According to a Cytokinetics media release, manuscript of REDWOOD-HCM Cohort 3 data published in the Journal of Cardiac Failure.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top